Trial
NCT04376827
A Study of Guselkumab in Participants With Active Lupus Nephritis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Lupus Nephritis
Intervention
Guselkumab Dose 1
Why stopped
Due to enrollment challenges, J\&J Innovative Medicine decided to stop screening and terminate the study early. This decision was not based on a safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-30